Fengmin Lu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/726748/publications.pdf

Version: 2024-02-01

116194 111975 5,445 142 36 67 citations h-index g-index papers 144 144 144 8745 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	A global survey of alternative splicing of HBV transcriptome using long-read sequencing. Journal of Hepatology, 2022, 76, 234-236.	1.8	5
2	Relationship between the Level of Serum Golgi Protein 73 and the Risk of Short-term Death in Patients with ALD-ACLF. Journal of Clinical and Translational Hepatology, 2022, 000, 000-000.	0.7	2
3	Diagnostic Value of Serum Golgi Protein 73 for Liver Inflammation in Patients with Autoimmune Hepatitis and Primary Biliary Cholangitis. Disease Markers, 2022, 2022, 1-7.	0.6	3
4	E2F1â€mediated AUF1 upregulation promotes HCC development and enhances drug resistance via stabilization of AKR1B10. Cancer Science, 2022, 113, 1154-1167.	1.7	26
5	MAP4K4 mediates the SOX6-induced autophagy and reduces the chemosensitivity of cervical cancer. Cell Death and Disease, 2022, 13, 13.	2.7	27
6	Active HBV replication in hypoxic pericentral zone 3 is up-regulated by multiple host factors including HIF- $1\hat{l}\pm$ Journal of Hepatology, 2022, , .	1.8	3
7	Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues. Journal of Viral Hepatitis, 2022, 29, 420-431.	1.0	6
8	Characterization and distribution of HIV-infected cells in semen. Emerging Microbes and Infections, 2022, 11, 860-872.	3.0	0
9	High dose sofosbuvir and sofosbuvir-plus-ribavirin therapy inhibit Hepatitis E Virus (HEV) replication in a rabbit model for acute HEV infection. Antiviral Research, 2022, 199, 105274.	1.9	9
10	SOX6-MAP4K4 pathway induces autophagy and contributes to the reduced chemosensitivity of cervical cancer., 2022, 1, 34-37.		0
11	A standardized assay for the quantitative detection of serum HBV RNA in chronic hepatitis B patients. Emerging Microbes and Infections, 2022, 11, 775-785.	3.0	7
12	<scp>LncCDCA3L</scp> inhibits cell proliferation via a novel <scp>RNA</scp> structureâ€based crosstalk with <scp>CDCA3</scp> in hepatocellular carcinoma. Liver International, 2022, 42, 1432-1446.	1.9	4
13	Immunocompromised rabbit model of chronic HEV reveals liver fibrosis and distinct efficacy of different vaccination strategies. Hepatology, 2022, 76, 788-802.	3.6	21
14	Letter to the editor: HBeAg expression suppressing/abolishing mutation elevated HBV DNA level in HBeAgâ€negative patients with chronic HBV infection. Hepatology, 2022, 76, E69-E70.	3.6	2
15	Solely HBsAg intrauterine exposure accelerates HBV clearance by promoting HBs-specific immune response in the mouse pups. Emerging Microbes and Infections, 2022, 11, 1356-1370.	3.0	1
16	Severe acute hepatitis in children with unknown aetiology, etiology analysis and the next action. Virologica Sinica, 2022, 37, 778-782.	1.2	4
17	Letter to the Editor: Why Serum Hepatitis B Virus (HBV) DNA Has Higher Frequency of rtM204I/V Mutation Than Serum HBV RNA in the Same Individual?. Hepatology, 2021, 73, 2075-2076.	3.6	1
18	Deletion of Golgi protein 73 delayed hepatocyte proliferation of mouse in the early stages of liver regeneration. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1346-1356.	1.4	3

#	Article	IF	CITATIONS
19	Reappraisal of the diagnostic value of alphaâ€fetoprotein for surveillance of HBVâ€related hepatocellular carcinoma in the era of antiviral therapy. Journal of Viral Hepatitis, 2021, 28, 20-29.	1.0	7
20	Cell Cycle Arrest Protein CDKN2C Is Not an HBV Host Factor. Virologica Sinica, 2021, 36, 810-813.	1.2	2
21	NFATc3 inhibits hepatocarcinogenesis and HBV replication via positively regulating RIG-I-mediated interferon transcription. Oncolmmunology, 2021, 10, 1869388.	2.1	11
22	Deoxycholic Acid Upregulates Serum Golgi Protein 73 through Activating NF-κB Pathway and Destroying Golgi Structure in Liver Disease. Biomolecules, 2021, 11, 205.	1.8	9
23	Neonatal hepatitis B vaccination protects mature adults from occult virus infection. Hepatology International, 2021, 15, 328-337.	1.9	6
24	Letter to the Editor: The Differences Between the Reverse Transcriptional Efficiency of HBV Pregenomic RNA and Transcriptional Efficiency of HBV Covalently Closed Circular DNA. Hepatology, 2021, 74, 1720-1721.	3.6	3
25	Prognostic value of HDL-related biomarkers in patients with HBV-related ACLF. Journal of Hepatology, 2021, 75, 243-245.	1.8	4
26	NEK7 Promotes Pancreatic Cancer Progression And Its Expression Is Correlated With Poor Prognosis. Frontiers in Oncology, 2021, 11, 705797.	1.3	13
27	Pacbio Sequencing of PLC/PRF/5 Cell Line and Clearance of HBV Integration Through CRISPR/Cas-9 System. Frontiers in Molecular Biosciences, 2021, 8, 676957.	1.6	6
28	Amino acid residues at core protein dimer-dimer interface modulate multiple steps of hepatitis B virus replication and HBeAg biogenesis. PLoS Pathogens, 2021, 17, e1010057.	2.1	10
29	Hepatitis B Virus Virions Produced Under Nucleos(t)ide Analogue Treatment Are Mainly Not Infectious Because of Irreversible DNA Chain Termination. Hepatology, 2020, 71, 463-476.	3 . 6	24
30	Association Between Negative Results From Tests for HBV DNA and RNA and Durability of Response After Discontinuation of Nucles(t)ide Analogue Therapy. Clinical Gastroenterology and Hepatology, 2020, 18, 719-727.e7.	2.4	72
31	Helicobacter pylori inhibits GKN1 expression via the CagA/pâ€ERK/AUF1 pathway. Helicobacter, 2020, 25, e12665.	1.6	17
32	Transient Chimeric Ad5/37 Fiber Enhances NK-92 Carrier Cell-Mediated Delivery of Oncolytic Adenovirus Type 5 to Tumor Cells. Molecular Therapy - Methods and Clinical Development, 2020, 18, 376-389.	1.8	13
33	Efficacy of a combination of HBV RNA and HBeAg in predicting HBeAg seroconversion in patients treated with entecavir for 144 weeks. International Journal of Infectious Diseases, 2020, 99, 171-178.	1.5	13
34	Is the lifeâ€long entecavir treatment really inevitable in chronic hepatitis B patients?. Journal of Viral Hepatitis, 2020, 27, 1509-1510.	1.0	0
35	Yin-Yang 1 and HBx protein activate HBV transcription by mediating the spatial interaction of cccDNA minichromosome with cellular chromosome $19p13.11$. Emerging Microbes and Infections, 2020 , 9 , $2455-2464$.	3.0	18
36	Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression During Therapy. Clinical Gastroenterology and Hepatology, 2020, 18, 2582-2591.e6.	2.4	57

#	Article	IF	Citations
37	Junceellolide B, a novel inhibitor of Hepatitis B virus. Bioorganic and Medicinal Chemistry, 2020, 28, 115603.	1.4	8
38	The Influence of Different Types of Serum Cholesterol on the Prognosis of Hepatitis B Virus-Related Hepatocellular Patients Needs More Attention. Gastroenterology, 2020, 159, 1190-1191.	0.6	0
39	Reply to: Correspondence relating to "SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19― Journal of Hepatology, 2020, 73, 996-998.	1.8	14
40	Serum Golgi Protein 73 as a Potential Biomarker for Hepatic Necroinflammation in Population with Nonalcoholic Steatohepatitis. Disease Markers, 2020, 2020, 1-7.	0.6	10
41	Sex-determining region Y box 4 (SOX4) suppresses Hepatitis B virus replication by inhibiting hepatocyte nuclear factor 4l± expression. Antiviral Research, 2020, 176, 104745.	1.9	5
42	Combined and sequential non-invasive approach to diagnosing non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease and persistently normal alanine aminotransferase levels. BMJ Open Diabetes Research and Care, 2020, 8, e001174.	1.2	21
43	HBV Genome and Life Cycle. Advances in Experimental Medicine and Biology, 2020, 1179, 17-37.	0.8	21
44	SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. Journal of Hepatology, 2020, 73, 807-816.	1.8	488
45	Monitoring of Serum HBV RNA, HBcrAg, HBsAg and anti-HBc Levels in Patients during Long-Term Nucleoside/Nucleotide Analogue Therapy. Antiviral Therapy, 2019, 24, 105-115.	0.6	35
46	Friend or Foe? Evidence Indicates Endogenous Exosomes Can Deliver Functional gRNA and Cas9 Protein. Small, 2019, 15, e1902686.	5.2	58
47	Gene Editing: Friend or Foe? Evidence Indicates Endogenous Exosomes Can Deliver Functional gRNA and Cas9 Protein (Small 38/2019). Small, 2019, 15, 1970205.	5.2	7
48	Exploring the Diagnostic Potential of Serum Golgi Protein 73 for Hepatic Necroinflammation and Fibrosis in Chronic HCV Infection with Different Stages of Liver Injuries. Disease Markers, 2019, 2019, 1-10.	0.6	10
49	Nonalcoholic fatty liver disease is associated with lower hepatitis B viral load and antiviral response in pediatric population. Journal of Gastroenterology, 2019, 54, 1096-1105.	2.3	11
50	Down-regulation of cell membrane localized NTCP expression in proliferating hepatocytes prevents hepatitis B virus infection. Emerging Microbes and Infections, 2019, 8, 879-894.	3.0	37
51	Long-term functional maintenance of primary human hepatocytes in vitro. Science, 2019, 364, 399-402.	6.0	147
52	<p>Elevated apolipoprotein B predicts poor postsurgery prognosis in patients with hepatocellular carcinoma</p> . OncoTargets and Therapy, 2019, Volume 12, 1957-1964.	1.0	18
53	Serum GP73 combined AST and GGT reflects moderate to severe liver inflammation in chronic hepatitis B. Clinica Chimica Acta, 2019, 493, 92-97.	0.5	18
54	A global scientific strategy to cure hepatitis B. The Lancet Gastroenterology and Hepatology, 2019, 4, 545-558.	3.7	342

#	Article	IF	CITATIONS
55	HBV T1719G mutation reduced HBV replication through mutant Enh II and HB x protein in vitro. Journal of Viral Hepatitis, 2019, 26, 710-717.	1.0	5
56	Over-gap PCR amplification to identify presence of replication-competent HBV DNA from integrated HBV DNA: An updated occult HBV infection definition. Journal of Hepatology, 2019, 70, 557-559.	1.8	10
57	Identification of <i>TAF1</i> , <i>HNF4A</i> , and <i>CALM2</i> as potential therapeutic target genes for liver fibrosis. Journal of Cellular Physiology, 2019, 234, 9045-9051.	2.0	24
58	Hepatocellular Carcinoma Surveillance and Treatment: A Way to Reduce Cancer-related Mortality in Cirrhotic Patients. Journal of Clinical and Translational Hepatology, 2019, 7, 1-2.	0.7	17
59	Liver Stiffness Measurement Can Reflect the Active Liver Necroinflammation in Population with Chronic Liver Disease: A Real-world Evidence Study. Journal of Clinical and Translational Hepatology, 2019, 7, 1-9.	0.7	6
60	Step layered combination of noninvasive fibrosis models improves diagnostic accuracy of advanced fibrosis in nonalcoholic fatty liver disease. Journal of Gastrointestinal and Liver Diseases, 2019, 28, 289-296.	0.5	11
61	Compensatory upregulation of aldo-keto reductase 1B10 to protect hepatocytes against oxidative stress during hepatocarcinogenesis. American Journal of Cancer Research, 2019, 9, 2730-2748.	1.4	5
62	<scp>RFX</scp> 1 participates in doxorubicinâ€induced hepatitis B virus reactivation. Cancer Medicine, 2018, 7, 2021-2033.	1.3	12
63	Integration of hepatitis B virus S gene impacts on hepatitis B surface antigen levels in patients with antiviral therapy. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1389-1396.	1.4	24
64	The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases: Experimental Data and Literature Review. Clinical Reviews in Allergy and Immunology, 2018, 54, 282-294.	2.9	36
65	Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-na \tilde{A} ve HBV-infected individuals. Journal of Clinical Virology, 2018, 99-100, 71-78.	1.6	63
66	HBV RNA virion-like particles produced under nucleos(t)ide analogues treatment are mainly replication-deficient. Journal of Hepatology, 2018, 68, 847-849.	1.8	27
67	Serum Golgi protein 73 is a marker comparable to APRI for diagnosing significant fibrosis in children with liver disease. Scientific Reports, 2018, 8, 16730.	1.6	11
68	Diacylglycerol kinase \hat{I}^3 predicts prognosis and functions as a tumor suppressor by negatively regulating glucose transporter 1 in hepatocellular carcinoma. Experimental Cell Research, 2018, 373, 211-220.	1.2	17
69	Serum HBV RNA is a Potential Predictor of Hepatitis B Surface Antigen Reversion. Hepatology Communications, 2018, 2, 1168-1171.	2.0	8
70	Early Env-specific CTLs effectively suppress viral replication in SHIV controller macaques. Cellular Immunology, 2018, 331, 30-37.	1.4	4
71	Methylation of PCDH19 predicts poor prognosis of hepatocellular carcinoma. Asia-Pacific Journal of Clinical Oncology, 2018, 14, e352-e358.	0.7	19
72	Integration of Prealbumin into Child-Pugh Classification Improves Prognosis Predicting Accuracy in HCC Patients Considering Curative Surgery. Journal of Clinical and Translational Hepatology, 2018, 6, 1-8.	0.7	9

#	Article	IF	CITATIONS
73	Long-distance interaction of the integrated HPV fragment with MYC gene and 8q24.22 region upregulating the allele-specific MYC expression in HeLa cells. International Journal of Cancer, 2017, 141, 540-548.	2.3	36
74	Complete genome sequencing and clinical analysis of intrahepatic hepatitis B virus cccDNA from HCC. Microbial Pathogenesis, 2017, 109, 49-55.	1.3	7
75	CRISPR/Cas9-mediated p53 and Pten dual mutation accelerates hepatocarcinogenesis in adult hepatitis B virus transgenic mice. Scientific Reports, 2017, 7, 2796.	1.6	44
76	PCDH9 acts as a tumor suppressor inducing tumor cell arrest at GO/G1 phase and is frequently methylated in hepatocellular carcinoma. Molecular Medicine Reports, 2017, 16, 4475-4482.	1.1	21
77	Reply to: "Serum HBV pgRNA as a clinical marker for cccDNA activity― Journal of Hepatology, 2017, 66, 462-463.	1.8	39
78	Potential use of serum HBV RNA in antiviral therapy for chronic hepatitis B in the era of nucleos(t)ide analogs. Frontiers of Medicine, 2017, 11, 502-508.	1.5	26
79	Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update). Journal of Clinical and Translational Hepatology, 2017, 5, 297-318.	0.7	181
80	The gRNA-miRNA-gRNA Ternary Cassette Combining CRISPR/Cas9 with RNAi Approach Strongly Inhibits Hepatitis B Virus Replication. Theranostics, 2017, 7, 3090-3105.	4.6	39
81	Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma. Oncotarget, 2017, 8, 16498-16506.	0.8	35
82	Down-regulation of NTCP expression by cyclin D1 in hepatitis B virus-related hepatocellular carcinoma has clinical significance. Oncotarget, 2017, 8, 56041-56050.	0.8	20
83	CCR6 B lymphocytes responding to tumor cell-derived CCL20 support hepatocellular carcinoma progression via enhancing angiogenesis. American Journal of Cancer Research, 2017, 7, 1151-1163.	1.4	12
84	Prognostic value of p53 mutation for poor outcome of Asian primary liver cancer patients: evidence from a cohort study and meta-analysis of 988 patients. OncoTargets and Therapy, 2016, Volume 9, 7425-7433.	1.0	11
85	Decreased Expression of BNC1 and BNC2 Is Associated with Genetic or Epigenetic Regulation in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2016, 17, 153.	1.8	14
86	Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis. Scientific Reports, 2016, 6, 19423.	1.6	42
87	Down-regulation of microRNA-9 leads to activation of IL-6/Jak/STAT3 pathway through directly targeting IL-6 in HeLa cell. Molecular Carcinogenesis, 2016, 55, 732-742.	1.3	42
88	Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy. Experimental and Therapeutic Medicine, 2016, 11, 117-123.	0.8	2
89	Dysregulation of host cellular genes targeted by human papillomavirus (<scp>HPV</scp>) integration contributes to <scp>HPV</scp> â€related cervical carcinogenesis. International Journal of Cancer, 2016, 138, 1163-1174.	2.3	54
90	Lamivudine-resistant rtL180M and rtM204l/V are persistently dominant during combination rescue therapy with entecavir and adefovir for hepatitis B. Experimental and Therapeutic Medicine, 2016, 11 , $2293-2299$.	0.8	4

#	Article	IF	CITATIONS
91	Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. Journal of Hepatology, 2016, 65, 700-710.	1.8	331
92	Failure recovery of circulating NKG2D ⁺ CD56 ^{dim} NK cells in HBV-associated hepatocellular carcinoma after hepatectomy predicts early recurrence. Oncolmmunology, 2016, 5, e1048061.	2.1	16
93	Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. Gut, 2016, 65, 313-320.	6.1	112
94	Alpha-fetoprotein still is a valuable diagnostic and prognosis predicting biomarker in hepatitis B virus infection-related hepatocellular carcinoma. Oncotarget, 2016, 7, 3702-3708.	0.8	49
95	Increased glyceraldehyde-3-phosphate dehydrogenase expression indicates higher survival rates in male patients with hepatitisÂB virus-accociated hepatocellular carcinoma and cirrhosis. Experimental and Therapeutic Medicine, 2015, 9, 1597-1604.	0.8	2
96	Alpha fetoprotein mediates <scp>HB</scp> x induced carcinogenesis in the hepatocyte cytoplasm. International Journal of Cancer, 2015, 137, 1818-1829.	2.3	42
97	Delayed Reduction of Hepatitis B Viral Load and Dynamics of Adefovir-Resistant Variants during Adefovir plus Entecavir Combination Rescue Therapy. International Journal of Medical Sciences, 2015, 12, 416-422.	1.1	4
98	Hepatitis B Virus X Protein Stabilizes Cyclin D1 and Increases Cyclin D1 Nuclear Accumulation through ERK-Mediated Inactivation of GSK-3β. Cancer Prevention Research, 2015, 8, 455-463.	0.7	20
99	Influence of CCND1 G870A polymorphism on the risk of HBV-related HCC and cyclin D1 splicing variant expression in Chinese population. Tumor Biology, 2015, 36, 6891-6900.	0.8	6
100	Reduced Red Blood Cell Count Predicts Poor Survival After Surgery in Patients With Primary Liver Cancer. Medicine (United States), 2015, 94, e577.	0.4	23
101	DNA methylation consistency implicates the primary tumor cell origin of recurrent hepatocellular carcinoma. Epigenomics, 2015, 7, 581-592.	1.0	16
102	CSIG promotes hepatocellular carcinoma proliferation by activating c-MYC expression. Oncotarget, 2015, 6, 4733-4744.	0.8	22
103	Comprehensive profiling of novel microRNA-9 targets and a tumor suppressor role of microRNA-9 via targeting IGF2BP1 in hepatocellular carcinoma. Oncotarget, 2015, 6, 42040-42052.	0.8	54
104	Phenotype and function of CXCR5+CD45RAâ^'CD4+ T cells were altered in HBV-related hepatocellular carcinoma and elevated serum CXCL13 predicted better prognosis. Oncotarget, 2015, 6, 44239-44253.	0.8	27
105	Dual gRNAs guided CRISPR/Cas9 system inhibits hepatitis B virus replication. World Journal of Gastroenterology, 2015, 21, 9554.	1.4	96
106	Analysis of Hepatitis B Virus Intrahepatic Covalently Closed Circular DNA and Serum Viral Markers in Treatment-Naive Patients with Acute and Chronic HBV Infection. PLoS ONE, 2014, 9, e89046.	1.1	31
107	Effectiveness of HCV core antigen and RNA quantification in HCV-infected and HCV/HIV-1-coinfected patients. BMC Infectious Diseases, 2014, 14, 577.	1.3	7
108	An unbalanced PD-L1/CD86 ratio in CD14++CD16+ monocytes is correlated with HCV viremia during chronic HCV infection. Cellular and Molecular Immunology, 2014, 11, 294-304.	4.8	20

#	Article	IF	CITATIONS
109	Protocadherin 9 inhibits epithelial–mesenchymal transition and cell migration through activating GSK-3β in hepatocellular carcinoma. Biochemical and Biophysical Research Communications, 2014, 452, 567-574.	1.0	42
110	The function of targeted host genes determines the oncogenicity of HBV integration in hepatocellular carcinoma. Journal of Hepatology, 2014, 60, 975-984.	1.8	95
111	Genetic polymorphisms of CXCR5 and CXCL13 are associated with non-responsiveness to the hepatitis B vaccine. Vaccine, 2014, 32, 5316-5322.	1.7	36
112	Alternative splicing variants of human Fbx4 disturb cyclin D1 proteolysis in human cancer. Biochemical and Biophysical Research Communications, 2014, 447, 158-164.	1.0	15
113	Coinfection with HIV-1 Alleviates Iron Accumulation in Patients with Chronic Hepatitis C Virus Infection. PLoS ONE, 2014, 9, e98039.	1.1	8
114	Extensive Recombination Due to Heteroduplexes Generates Large Amounts of Artificial Gene Fragments during PCR. PLoS ONE, 2014, 9, e106658.	1.1	23
115	Methylationâ€mediated repression of micro <scp>RNA</scp> 129â€2 enhances oncogenic <scp>SOX</scp> 4 expression in <scp>HCC</scp> . Liver International, 2013, 33, 476-486.	1.9	62
116	Serum hepatitis B surface antigen is correlated with intrahepatic total HBV DNA and cccDNA in treatmentâ€naà ve patients with chronic hepatitis B but not in patients with HBV related hepatocellular carcinoma. Journal of Medical Virology, 2013, 85, 219-227.	2.5	30
117	The involvement of Helicobacter pylori thioredoxin-1 in gastric carcinogenesis. Journal of Medical Microbiology, 2013, 62, 1226-1234.	0.7	17
118	Selection of reference genes for RT-qPCR analysis in tumor tissues from male hepatocellular carcinoma patients with hepatitis B infection and cirrhosis. Cancer Biomarkers, 2013, 13, 345-349.	0.8	16
119	Development and Evaluation of a Pseudovirus-Luciferase Assay for Rapid and Quantitative Detection of Neutralizing Antibodies against Enterovirus 71. PLoS ONE, 2013, 8, e64116.	1.1	25
120	Quantitative methylation analysis reveals gender and age differences in p16 <scp>INK</scp> 4a hypermethylation in hepatitis B virusâ€related hepatocellular carcinoma. Liver International, 2012, 32, 420-428.	1.9	44
121	AKR1B10 overexpression in breast cancer: Association with tumor size, lymph node metastasis and patient survival and its potential as a novel serum marker. International Journal of Cancer, 2012, 131, E862-71.	2.3	102
122	Alpha-fetoprotein acts as a novel signal molecule and mediates transcription of Fn14 in human hepatocellular carcinoma. Journal of Hepatology, 2012, 57, 322-329.	1.8	50
123	Re-evaluation of the Carcinogenic Significance of Hepatitis B Virus Integration in Hepatocarcinogenesis. PLoS ONE, 2012, 7, e40363.	1.1	59
124	Aberrant expression of microRNA 155 may accelerate cell proliferation by targeting sexâ€determining region Y box 6 in hepatocellular carcinoma. Cancer, 2012, 118, 2431-2442.	2.0	104
125	Antigenicity, animal protective effect and genetic characteristics of candidate vaccine strains of enterovirus 71. Archives of Virology, 2012, 157, 37-41.	0.9	44
126	Association of TNF-α Genetic Polymorphisms with Hepatocellular Carcinoma Susceptibility: A Case-Control Study in a Han Chinese Population. International Journal of Biological Markers, 2011, 26, 181-187.	0.7	22

#	Article	IF	CITATIONS
127	Impaired nuclear export of tumor-derived c-terminal truncated cyclin D1 mutant in ESCC cancer. Oncology Letters, 2011, 2, 1203-1211.	0.8	4
128	A Higher Correlation of HCV Core Antigen with CD4+ T Cell Counts Compared with HCV RNA in HCV/HIV-1 Coinfected Patients. PLoS ONE, 2011, 6, e23550.	1.1	10
129	Increased PDâ€L1 expression and PDâ€L1/CD86 ratio on dendritic cells were associated with impaired dendritic cells function in HCV infection. Journal of Medical Virology, 2010, 82, 1152-1159.	2.5	35
130	Association between epidermal growth factor 61A/G polymorphism and hepatocellular carcinoma susceptibility in Chinese patients. Liver International, 2010, 30, 112-118.	1.9	30
131	A role of functional T-type Ca2+ channel in hepatocellular carcinoma cell proliferation. Oncology Reports, 2009, 22, 1229-35.	1.2	22
132	No Association between EGF $+61$ A/G Polymorphism and Increased Risk of Glioma. International Journal of Biological Markers, 2009, 24, 77-82.	0.7	12
133	Synthesis and characterization of chitosan-based hydrogels. International Journal of Biological Macromolecules, 2009, 44, 121-127.	3.6	64
134	In Situ Mineralization of Hydroxyapatite on Electrospun Chitosanâ€Based Nanofibrous Scaffolds. Macromolecular Bioscience, 2008, 8, 239-246.	2.1	84
135	Mutations in Fbx4 Inhibit Dimerization of the SCFFbx4 Ligase and Contribute to Cyclin D1 Overexpression in Human Cancer. Cancer Cell, 2008, 14, 68-78.	7.7	135
136	T-type Ca2+ channel expression in human esophageal carcinomas: A functional role in proliferation. Cell Calcium, 2008, 43, 49-58.	1.1	69
137	Electrospun Water-Soluble Carboxyethyl Chitosan/Poly(vinyl alcohol) Nanofibrous Membrane as Potential Wound Dressing for Skin Regeneration. Biomacromolecules, 2008, 9, 349-354.	2.6	430
138	Tâ€type Ca 2+ Channel Expression in Human Esophageal Carcinomas: A Functional Role in Proliferation. FASEB Journal, 2007, 21, A538.	0.2	0
139	Gefitinib-sensitizing mutation in esophageal carcinoma cell line Kyse450. Cancer Biology and Therapy, 2006, 5, 152-155.	1.5	27
140	Is there a role for T-type Ca2+ channel in glioma cell proliferation?. Cell Calcium, 2005, 38, 593-595.	1.1	7
141	Conditional JAG1 Mutation Shows the Developing Heart Is More Sensitive Than Developing Liver to JAG1 Dosage. American Journal of Human Genetics, 2003, 72, 1065-1070.	2.6	55
142	An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Research, 2003, 63, 7056-61.	0.4	190